Sime Darby Motors (SDM) has partnered with the biopharmaceutical company AstraZeneca to accelerate the adoption of electric vehicles under Sime Darby Motors for AstraZeneca employees. The collaboration between the two companies was formalised through the signing of a Memorandum of Understanding (MoU) at the corporate headquarters of AstraZeneca, and was witnessed by representatives from the British High Commission, InvestKL Malaysia, and The British Malaysian Chamber of Commerce.
This is SDM’s first partnership formed with a biopharmaceutical company. The partnership would entail the provision of corporate rates to AstraZeneca’s employees to own an EV vehicle, particularly BMW, BYD, and Hyundai vehicles.
Sime Darby Motors Retail and Distribution for Southeast Asia, Hong Kong and Macau’s Managing Director, Jeffrey Gan said, “We have very clear EV ambitions at Sime Darby Motors and partners such as AstraZeneca play important roles as enablers in helping us achieve our target of a more energy-efficient product portfolio by 2025 and becoming a leader for EV in Malaysia.”
He added, “We are committed to supporting AstraZeneca in their transition to EV and this collaboration marks a crucial part of our efforts to achieve a wider EV adoption in Malaysia as well as to help achieve our mission to be future-ready in the automotive industry.”
AstraZeneca’s partnership with Sime Darby Motors also marked its commitment to transition into EVs. This is also in line with AstraZeneca’s decarbonisation strategy – the Ambition Zero Carbon sustainability programme, which aims to reduce carbon emissions and address climate change.